← Back to patent-cliff list
Candesartan Cilexetil/Rosuvastatin Calcium/Ezetimibe
Tier C — Watch / tradeCandesartan Cilexetil/Rosuvastatin Calcium/Ezetimibe
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：AT1, HMGCR, NPC1L1
Indications (approved)：Hyperlipoproteinaemia type II, Hypertension
Regional status
US
-
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Candesartan Cilexetil/Rosuvastatin Calcium/Ezetimibe?
Approved indications include: Hyperlipoproteinaemia type II, Hypertension.
When does the Candesartan Cilexetil/Rosuvastatin Calcium/Ezetimibe patent expire?
No public expiry year is available for Candesartan Cilexetil/Rosuvastatin Calcium/Ezetimibe yet; this page updates once verified.
How do I get a quote for Candesartan Cilexetil/Rosuvastatin Calcium/Ezetimibe intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30